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Abstract
Introduction Immediate-release memantine (10 mg, twice
daily) is approved in the USA for moderate-to-severe
Alzheimer’s disease (AD). This study evaluated the effi-
cacy, safety, and tolerability of a higher-dose, once-daily,
extended-release formulation in patients with moderate-to-
severe AD concurrently taking cholinesterase inhibitors.
Methods In this 24-week, double-blind, multinational
study (NCT00322153), outpatients with AD (Mini-Mental
State Examination scores of 3–14) were randomized to
receive once-daily, 28-mg, extended-release memantine or
placebo. Co-primary efficacy parameters were the baseline-
to-endpoint score change on the Severe Impairment Battery
(SIB) and the endpoint score on the Clinician’s Interview-Based
Impression of Change Plus Caregiver Input (CIBIC-Plus). The
secondary efficacy parameter was the baseline-to-endpoint
score change on the 19-item Alzheimer’s Disease Coop-
erative Study–Activities of Daily Living (ADCS–ADL19);
additional parameters included the baseline-to-endpoint
score changes on the Neuropsychiatric Inventory (NPI) and
verbal fluency test. Data were analyzed using a two-way
analysis of covariance model, except for CIBIC-Plus
(Cochran–Mantel–Haenszel test). Safety and tolerability
were assessed through adverse events and physical and
laboratory examinations.
Results A total of 677 patients were randomized to
receive extended-release memantine (n = 342) or placebo
(n = 335); completion rates were 79.8 and 81.2 %,
respectively. At endpoint (week 24, last observation carried
forward), memantine-treated patients significantly outper-
formed placebo-treated patients on the SIB (least squares
mean difference [95 % CI] 2.6 [1.0, 4.2]; p = 0.001),
CIBIC-Plus (p = 0.008), NPI (p = 0.005), and verbal
fluency test (p = 0.004); the effect did not achieve sig-
nificance on ADCS–ADL19 (p = 0.177). Adverse events
with a frequency of C5.0 % that were more prevalent in the
memantine group were headache (5.6 vs. 5.1 %) and
diarrhea (5.0 vs. 3.9 %).
Conclusion Extended-release memantine was efficacious,
safe, and well tolerated in this population.
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1 Introduction
The progression of Alzheimer’s disease (AD) to moderate
and severe stages is associated with increasing cognitive
and functional decline, greater dependence and burden on
caregivers, and higher direct and indirect costs, even in
non-institutionalized patients [1–4]. In addition, the chal-
lenges faced by community-dwelling patients with AD and
their caregivers are often aggravated by poor medication
adherence [5–7].
Memantine is an uncompetitive antagonist of N-methyl-
D-aspartate (NMDA) receptors, approved in the USA and
many countries worldwide for the treatment of moderate to
severe AD [8–10]. In the USA, it is currently administered
twice daily as an immediate-release formulation, with a
maximum recommended dosage of 20 mg/day. Considering
the problems associated with poor medication adherence
in AD, the availability of an extended-release, once-daily
memantine formulation would be expected to provide
improved convenience, and may potentially enable an
increased daily dosage without affecting the drug’s favorable
safety and tolerability profile [11, 12].
The objective of this study was to evaluate the efficacy,
safety, and tolerability of a novel, higher-dose (28-mg),
once-daily, extended-release memantine formulation in
outpatients with moderate-to-severe AD. Stable use of any
cholinesterase inhibitor was required in this study, similar
to a previous trial of immediate-release memantine (10 mg,
twice daily) in patients with moderate-to-severe AD who
were taking the cholinesterase inhibitor donepezil [9]. In
addition, the majority of participants in this study were
primarily of Hispanic origin (68.9 %), including partici-
pants from Argentina, Mexico, and Chile, a patient popu-
lation that has traditionally been under-represented in trials
of memantine and other AD drugs [13].
2 Methods
2.1 Participants
Study participants were community-dwelling men and
women of at least 50 years of age, with a clinical diagnosis
of probable AD using Diagnostic and Statistical Manual of
Mental Disorders-Text Revision (DSM-IV-TR) [14] and
National Institute of Neurological and Communicative
Disorders and Stroke–Alzheimer’s Disease and Related
Disorders Association (NINCDS–ADRDA) [15] criteria, a
Mini-Mental State Examination (MMSE) score [16] in the
3–14 range at screening and baseline, and results of a
magnetic resonance imaging (MRI) or computed tomog-
raphy (CT) scan (within the past 12 months) consistent
with this diagnosis. At screening, all participants were
required to be receiving ongoing cholinesterase inhibitor
therapy (stable dosage for at least 3 months) and to have
normal (or clinically non-significant) results on physical
examination, laboratory evaluations, and electrocardio-
gram (ECG).
Individuals were excluded from the study if, by the
judgment of the investigator, they had any of the following
(see Electronic Supplementary Material for a full list of
inclusion and exclusion criteria): clinically significant and
active pulmonary, gastrointestinal, renal, hepatic, endo-
crine, or cardiovascular system disease or cancer; a neu-
rologic disorder or dementia complicated by other organic
disease or predominant delusions; any DSM-IV Axis I
disorder other than AD; evidence of clinically significant
disease involving the central nervous system; systolic
hypertension or hypotension; a modified Hachinski Ische-
mia Score of[4 at screening; and current or prior exposure
to any unapproved concomitant medication that could not
be discontinued or switched to an allowable alternative
medication before baseline.
Written informed consent was provided by the patient’s
caregiver and either the patient (if possible) or a legally
acceptable representative. The study was designed to
comply with the International Conference on Harmoniza-
tion (ICH) guidance on General Considerations for Clinical
Trials (62 FR 6611, December 17, 1997), Nonclinical
Safety Studies for the Conduct of Human Clinical Trials
for Pharmaceuticals (62 FR 62922, November 25, 1997),
and Good Clinical Practice: Consolidated Guidance (62 FR
25692, May 9, 1997). The protocol was reviewed and
approved in the USA by an institutional review board for
each site, and by both an ethics committee and a Ministry
of Health agency within each of the other countries.
2.2 Trial Design
This study (MEM-MD-50; NCT00322153; http://clinical
trials.gov/show/NCT00322153) was a multinational, ran-
domized, double-blind, placebo-controlled, parallel-group
clinical trial in which participants were required to com-
plete between 4 and 14 days of single-blind placebo
treatment prior to baseline. At baseline, each patient was
randomized (1:1) to receive placebo or extended-release
memantine. The Statistical Programming department at
Forest Research Institute generated (using SAS, v. 9.1.3;
SAS Institute Inc., Cary, NC, USA) and maintained a list of
randomization codes in a secure area. At baseline, each
patient was sequentially assigned a randomization number
corresponding to treatment assignment. Medication corre-
sponding to the randomization numbers was provided to
each study site by Forest Laboratories. Patients assigned to
memantine initially received 7 mg/day (once daily), and
were up-titrated weekly in 7 mg/day increments, reaching
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the target dose of 28 mg at the beginning of week 4. By
week 8, patients were required to tolerate a minimum of
21 mg/day, or they were to be discontinued from the trial.
Study drug and placebo were administered in identically
appearing blister packs, either in the morning or evening,
and the dosing time remained consistent throughout the
study. Each blister pack contained a two-part, three-panel
label; the first remained on the pack, and the second and
third were placed in the case report form. The third panel
was sealed and contained the identity of the treatment in
the event of an emergency; no treatment assignment was
unblinded by this procedure or by any other procedure
prior to database lock. All study sites underwent pre-study
site feasibility and had to provide information to ensure
that the overall education, experience, and training of study
personnel were adequate to conduct clinical trials accord-
ing to good clinical practice, and that the investigators were
qualified and trained in both the treatment of AD and
clinical research. Investigators and relevant site personnel
were trained at an investigator meeting prior to the initia-
tion of the study, which included a protocol overview and a
review of study procedures, outcome measures, investiga-
tor responsibility, and recruitment. Outcome measures
were administered by trained and skilled individuals during
the trial.
2.3 Efficacy Parameters
The two co-primary efficacy parameters were baseline-to-
endpoint change on the Severe Impairment Battery (SIB)
total score [week 24, last-observation-carried-forward
(LOCF) approach] and the endpoint rating on the Clini-
cian’s Interview-Based Impression of Change Plus Care-
giver Input (CIBIC-Plus) scale (week 24, LOCF). The SIB
is a 40-item, 100-point scale, used to evaluate cognition in
patients with advanced dementia; lower scores indicate
greater impairment [17]. The CIBIC-Plus is a 7-point scale
used to assess the global clinical status of a patient, with
scores ranging from 1 (marked improvement) to 7 (marked
worsening); raters are blinded to data from other post-
baseline rating instruments and safety measures and do not
have access to prior post-baseline CIBIC-Plus ratings [18].
The secondary efficacy parameter was the change on the
19-item Alzheimer’s Disease Cooperative Study–Activities
of Daily Living (ADCS–ADL19) scale, a 54-point instru-
ment used to evaluate functional abilities in patients with
moderate to severe AD; lower scores indicate greater
impairment [19, 20]. Additional parameters included
changes on the Neuropsychiatric Inventory (NPI), a
12-item, 144-point scale used to measure the frequency and
severity of behavioral disturbances in patients with
dementia (higher scores indicate greater impairment), [21]
and the semantic verbal fluency test (VFT), in which
patients were assessed on the basis of the number of animals
they could name in 60 s [22]. All assessment scales were
administered at baseline and at the end of weeks 4, 8, 12, 18,
and 24, except the NPI, which was administered at weeks 8,
12, 18, and 24. The NPI caregiver distress rating, as well as
two exploratory health outcomes measures (the Modified
Resource Utilization in Dementia-Lite and the Caregiver
Perceived Burden Questionnaire) were also administered in
this study but were not analyzed for this report.
Measures of safety and tolerability included physical
examinations, measurements of vital signs, laboratory tests
(hematology, blood chemistry, and urinalysis), ECGs, and
recordings of adverse events. Blood and urine samples
were collected and ECGs were taken at screening and week
24; adverse events and vital signs were recorded at baseline
and at each post-baseline visit. Any clinical findings dis-
covered during the final examination, or at premature dis-
continuation, were followed until the condition returned to
pre-study status or could be explained as being unrelated to
the study drug. A follow-up visit could be scheduled within
30 days of termination, as needed.
Adverse events were solicited from patients and care-
givers at all study visits (and during any contact with a
patient or patient representative occurring outside of a
defined study visit, including any contact up to 30 days after
study completion), using non-leading questions such as
‘‘How do you feel?’’ Adverse events were coded according
to the Medical Dictionary for Regulatory Activities (version
7.0 or newer), and an assessment of the severity, chronicity,
causal relationship to study medication, and seriousness of
the event was provided by an investigator. An adverse event
was considered to be treatment emergent if it was not
present prior to the first dose of double-blind study medi-
cation, or if it increased in severity following the dosing.
Patients who experienced more than one adverse event
within a specific category were counted only once.
2.4 Statistical Analysis
The study sample size was calculated on the basis of week
24 (LOCF) effect sizes (0.40 for SIB; 0.24 for CIBIC-Plus)
established in a previous study of memantine (10 mg/day,
twice daily) in patients with moderate to severe AD who
were receiving stable, concomitant donepezil treatment [9].
Assuming that these effect sizes are the true treatment
effects for extended-release memantine, a sample size of
300 patients per group was needed to provide a power of at
least 83 % to detect these effect sizes (or greater) simul-
taneously at a significance level of 0.05 (two-sided).
The safety population consisted of all randomized
patients who received at least one dose of double-blind
study medication. The intent-to-treat (ITT) population
consisted of all patients from the safety population who
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completed at least one post-baseline primary efficacy
assessment (SIB or CIBIC-Plus). Primary efficacy analyses
were based on the ITT population and the LOCF approach
for imputation of missing values. The changes from base-
line to week 24 (LOCF) in SIB scores were analyzed (by
Forest Research Institute) by means of a two-way analysis
of covariance (ANCOVA) model, with treatment group
and study center as factors and baseline as a covariate; the
week 24 (LOCF) CIBIC-Plus scores were analyzed using a
Cochran–Mantel–Haenszel test with modified ridit scores,
controlling for study center. Secondary (ADCS–ADL19)
and additional efficacy parameters (NPI, VFT) were ana-
lyzed using the ANCOVA model. Additional analyses for
all outcomes included the use of observed cases (OC) in the
same models. For the two co-primary parameters, a sen-
sitivity analysis using a mixed-effects model for repeated
measures (MMRM) based on OC data was also performed,
using treatment, visit, and treatment-by-visit interaction as
factors and baseline score (SIB or Clinician’s Interview-
Based Impression of Severity) as a covariate. For all
statistical analyses, the significance level was 0.05 (two-
sided). No interim analyses were planned or performed.
The number and percentage of patients with treat-
ment-emergent adverse events in each treatment group
were tabulated by system organ class, preferred term,
severity, and relationship to the study drug. The number
and percentage of patients with any treatment-emergent
adverse events, serious adverse events, and adverse
events leading to premature discontinuations were pre-
sented by treatment group, system organ class, and
preferred term.
3 Results
The study was conducted at 83 medical research centers in
four countries (Argentina: 23 centers, 311 patients; USA:
38 centers, 179 patients; Mexico: 11 centers, 97 patients;
Chile: 11 centers, 90 patients), between June 2005 and
October 2007.
A total of 677 participants were randomized (1:1) to
receive either placebo (n = 335) or extended-release me-
mantine (n = 342), with 272 (81.2 %) and 273 (79.8 %)
participants completing the trial, respectively (Fig. 1). By
the end of the study, the mean daily dose of extended-
release memantine was 27.0 mg, with a total of 314
patients (92.1 %) receiving the maximum daily dose of
28 mg. The treatment groups were well matched for
demographic and clinical characteristics at baseline
(Table 1). All participants were in the range of moderate-
to-severe AD (MMSE range of 3–14 at screening and 3–17
at baseline; mean Functional Assessment Staging [23]
between 6a and 6b at screening). The majority of
participants were of Hispanic origin (placebo 69.6 %,
memantine 68.3 %).
3.1 Co-primary Efficacy Parameters
At week 24, the extended-release memantine group sig-
nificantly outperformed the placebo group on both the SIB
(Fig. 2a; Table 2) and the CIBIC-Plus (Fig. 2b; Table 2).
In addition, the memantine group significantly outper-
formed the placebo group at week 12 on the SIB (OC) and
CIBIC-Plus (OC, LOCF) and at week 18 on the SIB (OC,
LOCF) (OC data presented in Fig. 2a, b).
Fig. 1 Study flow. *One patient with a protocol violation was
excluded prior to receiving study medication and was not included in
the safety population. ChEI cholinesterase inhibitor, ER extended-
release formulation (28 mg), ITT intent-to-treat population
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3.2 Secondary and Additional Efficacy Assessments
At week 24, there were no significant differences between
the treatment groups on the ADCS–ADL19 (Fig. 2c;
Table 2), but the extended-release memantine group sig-
nificantly outperformed the placebo group on the NPI
(Fig. 2d; Table 2) and on the VFT (Fig. 2e; Table 2). In
addition, for both the NPI and the VFT, memantine was
associated with significant benefits over placebo at weeks
12 and 18 (OC data presented in Fig. 2d, e).
3.3 Safety and Tolerability
A total of 21/335 patients (6.3 %) in the placebo group and
34/341 patients (9.9 %) in the extended-release memantine
group discontinued the trial because of an adverse event
(Fig. 1). The most frequent reasons for discontinuation
due to an adverse event were dizziness [placebo 0 (0 %),
memantine 5 (1.5 %)] and agitation [placebo 1 (0.3 %),
memantine 3 (0.9 %)]. A total of 214 placebo-treated
(63.9 %) and 214 memantine-treated patients (62.8 %)
reported treatment-emergent adverse events, with both
groups reporting, in general, a similar adverse-event profile
(Table 3).
Serious adverse events were experienced by 21 pla-
cebo-treated (6.3 %) and 28 memantine-treated patients
(8.2 %), with fall [placebo 5 (1.5 %), memantine 2
(0.6 %)] and urinary tract infection [placebo 3 (0.9 %),
memantine 2 (0.6 %)] being the most frequent. Pneumo-
nia, cerebrovascular accident, and syncope were the only
other serious adverse events experienced by more than
one patient in the memantine-treated group [placebo 0,
memantine 2 (0.6 %), for each]. Nine patients out of 676
died during the trial: 5 (1.5 %) in the placebo group and 4
(1.2 %) in the memantine group. No death was judged to
be related or possibly related to treatment in the me-
mantine-treated group.
A greater than twofold difference in the rate of poten-
tially clinically significant (PCS) laboratory values was
observed for low hemoglobin [placebo 3 (1.1 %), me-
mantine 7 (2.4 %)] and high eosinophil levels [placebo 4
(1.4 %), memantine 1 (0.3 %)]; the rates of other PCS
laboratory values were similar between the treatment
groups.
4 Discussion
This study, similar in design to three previous memantine
trials in moderate to severe AD [8, 9, 24], including a
trial in patients on stable cholinesterase inhibitor therapy
(donepezil) [9], demonstrated a significant advantage of
extended-release memantine (28 mg) over placebo on
multiple outcome measures. Patients treated with extended-
release memantine performed significantly better than
placebo-treated patients on the co-primary outcome mea-
sures of cognition and global clinical status, as well as on
the measures of behavior and verbal fluency. In contrast to
two of the previous studies in patients with moderate to
severe AD [8, 9], no significant difference between treat-
ment groups was observed on the ADCS–ADL19. In the
current study, patients in both groups remained stable or
demonstrated a slight decline after 24 weeks, whereas in
the other two studies, placebo-treated patients declined by
an average of 5.9 points [8] and 3.3 points [9], respectively
(OC analyses). In the other previous trial, which investi-
gated memantine monotherapy, placebo-treated patients
declined by an average of 2.3 points, and no differences
between groups were observed [24].
It should be noted that our study consisted of a large,
mostly non-US Hispanic population (69 %), which has not






Age, yearsa 76.8 ± 7.8 76.2 ± 8.4
Women, n (%) 243 (72.5) 244 (71.6)
White, n (%) 312 (93.1) 324 (95.0)
Hispanic, n (%) 233 (69.6) 233 (68.3)
Weight, kga 64.7 ± 13.3 65.1 ± 12.8
Education, yearsa 8.9 ± 4.5 8.8 ± 4.5
MMSE scorea 10.6 ± 2.9 10.9 ± 2.9
MMSE range 3–15 3–17
mHIS (at screening)a 1.1 ± 0.98 1.1 ± 0.92
FAST score (at screening)a,b 1.3 ± 2.2 1.2 ± 2.1
Concomitant ChEI treatment at baseline
Donepezil
Patients, n (%) 228 (68.1) 236 (69.2)
Treatment duration, monthsa 17.5 ± 18.4 16.9 ± 18.3
Mean dose, mg/daya 7.8 ± 2.6 8.0 ± 2.8
Galantamine
Patients, n (%) 68 (20.3) 72 (21.1)
Treatment duration, monthsa 14.2 ± 12.2 16.1 ± 18.2
Mean dose, mg/daya 13.5 ± 5.4 13.5 ± 5.7
Rivastigmine
Patients, n (%) 41 (12.2) 32 (9.4)
Treatment duration, monthsa 16.8 ± 18.8 17.4 ± 16.9
Mean dose, mg/daya 6.8 ± 2.9 6.8 ± 2.6
a Mean ± standard deviation
b FAST was administered at screening only; stages 1, 2, 3,… 7f were
assigned numerical values of -4, -3, -2, … 11
ChEI cholinesterase inhibitor, ER extended-release formulation
(28 mg), FAST Functional Assessment Staging, MMSE Mini-Mental
State Examination, mHIS modified Hachinski Ischemia Score
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Fig. 2 Efficacy outcomes. In ChEI-treated patients with moderate to
severe AD, treatment with memantine ER provided significant
benefits on primary measures of cognition [(a) SIB] and global status
[(b) CIBIC-Plus], as well as secondary measures of behavior
[(d) NPI] and verbal fluency (e). No statistically significant differ-
ences were observed on the measure of function [(c) ADCS–ADL19].
AD Alzheimer’s disease, ADCS–ADL19 19-item Alzheimer’s Disease
Cooperative Study–Activities of Daily Living, ChEI cholinesterase
inhibitor, CIBIC-Plus Clinician’s Interview-Based Impression of
Change Plus Caregiver Input, ER extended-release formulation (28
mg), LOCF last observation carried forward, LS least squares, MMRM
mixed-effects model for repeated measures, NPI Neuropsychiatric
Inventory, OC observed cases, SEM standard error of the mean, SIB
Severe Impairment Battery. *p \ 0.05; **p \ 0.01; ***p \ 0.001; p-
values indicating statistically significant differences between groups
are shown in bold type
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been extensively represented in clinical trials in AD [13].
Although other ADL measures have been successfully
validated in Hispanic patients [25–27], to our knowledge
the only Spanish validation of the ADCS–ADL scale
involves the 23-item instrument in Spanish-speaking
Americans [28], and the possibility exists that some items
from the 19-item scale may be less applicable to patients
with moderate to severe AD from Central or South
America.
Also, we find it noteworthy that extended-release me-
mantine treatment demonstrated significant benefits on
behavioral symptoms (NPI), in spite of a robust placebo
response (Fig. 2d). A protocol-specified analysis of indi-
vidual NPI items (not reported here) showed a significant
advantage for memantine over placebo on agitation/
aggression, irritability/lability, nighttime behavior, and
delusions, which is consistent with previous studies [10,
29–31]. Since behavioral symptoms are associated with
increased severity of dementia, functional decline, proba-
bility of institutionalization, patient care costs, and care-
giver burden [32–34], an improvement in their
management should translate into a tangible, clinically
important benefit.
Memantine treatment in this trial was also associated
with significant improvements in semantic fluency [22].
The semantic fluency task requires attention, information
retrieval, and intact semantic associations [35–37], and is
strongly dependent upon the hippocampus and related
structures in the left mediotemporal lobe [38, 39].
In patients with AD, semantic fluency positively correlates
with measures of memory [40] and the ability to perform
everyday activities [35].
This study was unique for a number of reasons. First, we
examined the efficacy of a higher-dose, extended-release
formulation of memantine. Although the currently approved
immediate-release formulation in principle has a sufficient
half-life to enable once-daily dosing (60–80 h) [12, 41], the
extended-release formulation allows for a higher target dose
[48 % higher steady-state maximum plasma concentration
(Cmax) and 33 % higher area under the plasma concentra-
tion–time curve from time 0 to 24 h (AUC0–24), compared
with twice-daily 10-mg dosing of immediate-release
memantine; data on file, Forest Research Institute] and
provides a slow release, which could contribute to reducing
the rate and severity of adverse reactions resulting from
rapid drug absorption. Patients in the extended-release
memantine group experienced very few adverse events
(Table 3), which were consistent but generally lower in
frequency compared with those seen in similar, previous
studies of immediate-release memantine in patients with
moderate to severe AD [8, 9, 11, 12, 24]; however, a dif-
ferent study design would be required to properly assess
Table 2 Mean efficacy assessments at baseline and endpoint (week 24, LOCF; ITT population)
Outcome measure N Baselinea Endpoint change from baselinea LSMD [95 % CI] p-Value
SIB
Memantine ER 332 76.8 ± 17.5 2.7 ± 11.2 2.6 [1.0, 4.2] 0.001
Placebo 327 75.2 ± 19.3 0.3 ± 11.5
CIBIC-Plusb
Memantine ER 333 4.5 ± 0.87 3.8 ± 1.2b N/A 0.008
Placebo 328 4.5 ± 0.82 4.1 ± 1.2b
ADCS–ADL19
Memantine ER 331 33.1 ± 11.1 -0.7 ± 6.9 0.7 [-0.3, 1.8] 0.177
Placebo 328 32.8 ± 11.0 -1.3 ± 7.7
NPI
Memantine ER 318 17.2 ± 15.6 -4.3 ± 14.6 -2.7 [-4.5, -0.8] 0.005
Placebo 321 16.5 ± 15.4 -1.6 ± 12.7
VFT
Memantine ER 330 5.8 ± 3.8 0.3 ± 2.8 0.5 [0.2, 0.9] 0.004
Placebo 326 5.7 ± 3.7 -0.3 ± 2.5
a Mean ± standard deviation
b CIBIC-Plus is a categorical measure of change. Values shown for baseline are the Clinician’s Interview-Based Impression of Severity;
endpoint values are final CIBIC-Plus scores. p-Value is from a Cochran–Mantel–Haenszel test
ADCS–ADL19 19-item Alzheimer’s Disease Cooperative Study–Activities of Daily Living, CI confidence interval, CIBIC-Plus Clinician’s
Interview-Based Impression of Change Plus Caregiver Input, ER extended-release formulation (28 mg), ITT intent-to-treat, LOCF last obser-
vation carried forward, LSMD least squares mean difference, N/A not applicable, NPI Neuropsychiatric Inventory, SIB Severe Impairment
Battery, VFT verbal fluency test
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differences between the two formulations. Secondly, this
trial allowed concomitant treatment with any of the three
currently approved cholinesterase inhibitors; in the only
other randomized trial of memantine in patients with
moderate to severe AD taking cholinesterase inhibitors, all
patients were taking donepezil [9]. The inclusion of a
measure of verbal fluency is also unique; to our knowledge,
only one other placebo-controlled trial of an approved anti-
dementia drug has used verbal fluency as an outcome
measure in patients with AD. In that study, donepezil did
not improve phonemic fluency in patients with mild-to-
moderate dementia [42]. Finally, this study was performed
in a population that was predominantly Hispanic, a popu-
lation that has traditionally been under-represented in trials
of anti-dementia drugs [13].
A notable limitation of this study was the absence of an
active control arm containing patients treated with stan-
dard, immediate-release memantine. Consequently, the
new 28-mg extended-release formulation cannot be
directly compared with standard dosing in terms of effi-
cacy, adverse events, or adherence to drug. In addition, in
order to limit the confounding effects of multiple comor-
bidities and the exposure of frail individuals to an inactive
placebo treatment, this study recruited outpatients who met
a set of entry criteria comparable to those typically found
in clinical trials of anti-dementia therapies, but which may
not be fully representative of an actual out-of-trial popu-
lation. We recommend that each of these parameters be
addressed in future trials. Furthermore, a number of post
hoc analyses could provide interesting and useful infor-
mation, including comparisons between Hispanic and non-
Hispanic patients and analyses by the type of cholinester-
ase inhibitor used. The primary statistical analysis in this
study utilized the LOCF approach (an FDA standard at the
time of the trial), in which imputation of missing scores is
performed using the most recent available values. Since
this approach has the potential to create a bias when used in
trials of conditions associated with steady clinical decline,
such as AD [43], supportive analyses using OC and
MMRM were also performed, and showed nearly identical
results (Fig. 2).
5 Conclusion
This trial of a novel, 28-mg, extended-release memantine
formulation supports the existing body of evidence that
indicates memantine provides cognitive, global, and
behavioral benefits in patients with moderate to severe AD
treated with a cholinesterase inhibitor, while the new for-
mulation allows for an increased daily dose and simplified
delivery regimen. Studies that directly compare the new
extended-release formulation with standard dosing should
be conducted to further assess efficacy, drug adherence,
and caregiver burden.
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